Jane L Burns
Affiliation: University of Washington
- Culture-based diagnostic microbiology in cystic fibrosis: can we simplify the complexity?Jane L Burns
Seattle Children s Hospital, University of Washington School of Medicine, Department of Pediatrics, Division of Infectious Diseases, Seattle, WA, USA Electronic address
J Cyst Fibros 13:1-9. 2014....
- Respiratory viruses in children with cystic fibrosis: viral detection and clinical findingsJane L Burns
Department of Pediatrics, Division of Infectious Diseases, University of Washington and Seattle Children s Hospital, USA
Influenza Other Respir Viruses 6:218-23. 2012..In addition, associations between viral detection and respiratory symptoms are not well described...
- Use of phage display to identify potential Pseudomonas aeruginosa gene products relevant to early cystic fibrosis airway infectionsChristiane Beckmann
Infectious Diseases Section, Children s Hospital and Regional Medical Center, 307 Westlake Ave N, Suite 300, Seattle, WA 98109, USA
Infect Immun 73:444-52. 2005..These results demonstrate the feasibility and validity of this novel approach and suggest potential targets for future development...
- Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosisScott D Sagel
Department of Pediatrics, The Children s Hospital and University of Colorado Health Sciences Center, Aurora, CO 80045, USA
J Pediatr 154:183-8. 2009..To assess the effects of Pseudomonas aeruginosa and Staphylococcus aureus infection on lower airway inflammation and clinical status in young children with cystic fibrosis (CF)...
- Growth phenotypes of Pseudomonas aeruginosa lasR mutants adapted to the airways of cystic fibrosis patientsDavid A D'Argenio
Department of Microbiology, University of Washington, Seattle, WA, USA
Mol Microbiol 64:512-33. 2007..Loss of LasR function may represent a marker of an early stage in chronic infection of the CF airway with clinical implications for antibiotic resistance and disease progression...
- Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosaLisa Saiman
Department of Pediatrics, Columbia University, New York, New York 10032, USA
Pediatr Pulmonol 47:641-8. 2012..We now report the results of the open-label, follow-on study to assess durability of response to azithromycin and continued safety and tolerability...
- Pseudomonas aeruginosa lasR mutants are associated with cystic fibrosis lung disease progressionLucas R Hoffman
Department of Pediatrics, University of Washington School of Medicine, Seattle, WA 98195, USA
J Cyst Fibros 8:66-70. 2009..Pseudomonas aeruginosa with mutations in the transcriptional regulator LasR chronically infect the airways of people with cystic fibrosis (CF), yet the prevalence and clinical implications of lasR mutant infection are unknown...
- Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosisNicole Mayer-Hamblett
Department of Pediatrics, University of Washington, Seattle, Washington Seattle Children s Hospital, Seattle, Washington, USA
Pediatr Pulmonol 47:125-34. 2012..The risk of pulmonary exacerbation following Pseudomonas aeruginosa (Pa) acquisition in children with cystic fibrosis (CF) is unknown...
- Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infectionSamuel M Moskowitz
Department of Pediatrics, Massachusetts General Hospital, Boston, Massachusetts Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington Seattle Children s Hospital, Seattle, Washington
Pediatr Pulmonol 46:184-92. 2011..In cystic fibrosis (CF), conventional antibiotic susceptibility results correlate poorly with clinical outcomes. We hypothesized that biofilm testing would more accurately reflect the susceptibilities of bacteria infecting CF airways...
- Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trialLisa Saiman
Columbia University, Department of Pediatrics, 650 W 168th St, PH 4 West, Room 420, New York, NY 10032, USA
JAMA 303:1707-15. 2010..Azithromycin is recommended as therapy for cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa infection, but there has not been sufficient evidence to support the benefit of azithromycin in other patients with CF...
- Characterization of small-colony-variant Stenotrophomonas maltophilia isolated from the sputum specimens of five patients with cystic fibrosisScott W Anderson
Department of Laboratories and Pathology, Children s Hospital and Regional Medical Center, University of Washington School of Medicine, Seattle, WA 98105, USA
J Clin Microbiol 45:529-35. 2007..maltophilia phenotype and SXT resistance by interference with the dihydrofolate reductase pathway. Recovery of SCV S. maltophilia from the sputum of CF patients has implications for both laboratory testing and patient management...
- Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008Julia Emerson
Seattle Children s Hospital, Seattle, Washington 98101, USA
Pediatr Pulmonol 45:363-70. 2010..The study objective was to identify changes in cystic fibrosis (CF) sputum microbiology over 13 years...
- Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patientsEric E Smith
Genome Center, Program in Molecular and Cellular Biology, University of Washington, Seattle, WA 98195, USA
Proc Natl Acad Sci U S A 103:8487-92. 2006..aeruginosa strains present in advanced CF infections differ systematically from those of "wild-type" P. aeruginosa and that these differences may offer new opportunities for treatment of this chronic disease...
- A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infectionGeorge Z Retsch-Bogart
Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7220, USA
Pediatr Pulmonol 43:47-58. 2008..Aztreonam lysine for inhalation (AZLI) is being developed for treatment of CF patients with Pseudomonas aeruginosa airway infection...
- Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypesDao Nguyen
Children s Hospital and Regional Medical Center, Seattle, Washington, USA
Pediatr Pulmonol 42:533-41. 2007..The in vitro effect of AZM on PLC correlates with FEV(1) response to AZM. This suggests that AZM anti-virulence effects may be predictive of clinical response and play a role in the mechanism of action of AZM in CF patients...
- Unique lipid a modifications in Pseudomonas aeruginosa isolated from the airways of patients with cystic fibrosisRobert K Ernst
Department of Medicine, University of Washington, Seattle, WA 98195, USA
J Infect Dis 196:1088-92. 2007..None of the isolates from the environment or from patients with other conditions displayed these modifications. These results indicate that unique lipid A modifications occur in clinical P. aeruginosa CF isolates...
- Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosisRonald L Gibson
Department of Pediatrics, University of Washington Children s Hospital and Regional Medical Center, Seattle, WA 98105 0371, USA
Pediatr Pulmonol 42:610-23. 2007..Early intervention strategies include tobramycin solution for inhalation (TSI), which can eradicate lower airway Pa from cultures obtained at the end of 28 days of treatment in young children...
- Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosisRonald L Gibson
Department of Pediatrics, Children s Hospital and Regional Medical Center University of Washington, Seattle, Washington 98105 0371, USA
Am J Respir Crit Care Med 167:841-9. 2003..We conclude that 28 days of tobramycin solution for inhalation of 300 mg twice daily is safe and effective for significant reduction of lower airway Pa density in young children with cystic fibrosis...
- Pandoraea bacteremia in a cystic fibrosis patient with associated systemic illnessLindsey N Johnson
Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA
Pediatr Infect Dis J 23:881-2. 2004..We describe a case of Pandoraea bacteremia in a 16-year-old cystic fibrosis patient associated with clinical disease, suggesting that this organism should be considered a true pathogen in susceptible patients...
- Nutrient availability as a mechanism for selection of antibiotic tolerant Pseudomonas aeruginosa within the CF airwayLucas R Hoffman
Department of Pediatrics, University of Washington, Seattle, Washington, USA
PLoS Pathog 6:e1000712. 2010....
- Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosisMiriam M Treggiari
Department of Anesthesiology and Pain Medicine, Seattle Children s Hospital, WA 98104, USA
Arch Pediatr Adolesc Med 165:847-56. 2011..To investigate the efficacy and safety of 4 antipseudomonal treatments in children with cystic fibrosis with recently acquired Pseudomonas aeruginosa infection...
- Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosisArnold L Smith
Seattle Biomedical Research Institute, WA 98109, USA
Chest 123:1495-502. 2003..The susceptibility of the P aeruginosa isolates to ceftazidime and tobramycin was determined at trial enrollment by broth microdilution...
- Pathophysiology and management of pulmonary infections in cystic fibrosisRonald L Gibson
Department of Pediatrics, University of Washington School of Medicine, Children s Hospital, Seattle, WA 98125, USA
Am J Respir Crit Care Med 168:918-51. 2003..In addition, the article discusses infection control policies, therapies to optimize airway clearance and reduce inflammation, and potential future therapies...
- Genome mosaicism is conserved but not unique in Pseudomonas aeruginosa isolates from the airways of young children with cystic fibrosisRobert K Ernst
Department of Microbiology, University of Washington, Health Sciences Building, K 140, Box 357710, Seattle, WA 98195, USA
Environ Microbiol 5:1341-9. 2003..Further characterization of P. aeruginosa diversity within the airways of individual CF patients may reveal common adaptations, perhaps mediated by gene loss, that suggest new opportunities for therapy...
- Sputum tobramycin concentrations in cystic fibrosis patients with repeated administration of inhaled tobramycinJennifer Ruddy
Department of Pediatrics, Seattle Children s Hospital and University of Washington, Seattle, WA 98105, USA
J Aerosol Med Pulm Drug Deliv 26:69-75. 2013....
- Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosisClaudia L Ordonez
Department of Pediatrics, Harvard Medical School, Boston, MA 02215, USA
Am J Respir Crit Care Med 168:1471-5. 2003..Seven of 127 (6%) sputum induction procedures showed a decrease in FEV1 of 20% or more. We conclude that markers in induced sputum may be useful, noninvasive outcome measures to assess response to therapies in cystic fibrosis studies...
- Association between pulmonary function and sputum biomarkers in cystic fibrosisNicole Mayer-Hamblett
Department of Pediatrics, University of Washington, 4800 Sand Point Way N E, Box 5371, Seattle, WA 98105 0371, USA
Am J Respir Crit Care Med 175:822-8. 2007..Validation of these biomarkers as correlates of disease severity is a key step for their application...
- Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosisRonald L Gibson
Department of Pediatrics, University of Washington, Children s Hospital and Regional Medical Center, Seattle, Washington 98105 0371, USA
Pediatr Pulmonol 41:656-65. 2006..Aztreonam lysinate for inhalation (AI) is a novel monobactam formulation being investigated for pulmonary Pseudomonas aeruginosa infections in patients with cystic fibrosis (CF)...
- Hypermutable Haemophilus influenzae with mutations in mutS are found in cystic fibrosis sputumMichael E Watson
Seattle Biomedical Research Institute, 307 Westlake Ave N, Suite 500, Seattle, WA 98109, USA
Microbiology 150:2947-58. 2004..Hypermutable H. influenzae with mutations in mutS are prevalent, particularly in the CF lung environment, and may be selected for and maintained by antibiotic pressure...
- Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosisSamuel M Moskowitz
Department of Pediatrics, University of Washington School of Medicine, and Division of Pulmonary Medicine, Children s Hospital and Regional Medical Center, Seattle, USA
J Clin Microbiol 42:1915-22. 2004....
- Staphylococcus aureus small-colony variants are independently associated with worse lung disease in children with cystic fibrosisDaniel J Wolter
Departments of Pediatrics, University of Washington, Seattle, WA 98105, USA
Clin Infect Dis 57:384-91. 2013..We sought to determine the prevalence, clinical significance, and likely mechanisms of selection of S. aureus SCVs among a US cohort of children with CF...
- Pseudomonas aeruginosa syntrophy in chronically colonized airways of cystic fibrosis patientsXuan Qin
Microbiology Laboratory, Department of Laboratories and Pathology, Seattle, Washington, USA
Antimicrob Agents Chemother 56:5971-81. 2012..We propose that P. aeruginosa adopts a multicellular lifestyle in CF patients due to host selection of an energetically favorable, less-virulent microbe restricted within and symbiotic with the airway over the host's lifetime...
- Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasisDavid L MacLeod
Gilead Sciences, Inc, Seattle, WA 98121, USA
J Antimicrob Chemother 64:829-36. 2009..To compare the in vitro and in vivo activities of a 4:1 (w/w) fosfomycin/tobramycin combination (FTI) with those of fosfomycin and tobramycin alone against cystic fibrosis (CF) and non-CF bronchiectasis pathogens...
- Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trialLisa Saiman
Department of Pediatrics, Columbia University College of Physicians and Surgeons, New York, NY 10032 3784, USA
JAMA 290:1749-56. 2003..Treatment strategies for cystic fibrosis (CF) lung disease include antibiotics, mucolytics, and anti-inflammatory therapies. Increasing evidence suggests that macrolide antibiotics might be beneficial in patients with CF...
- Use of Pseudomonas biofilm susceptibilities to assign simulated antibiotic regimens for cystic fibrosis airway infectionSamuel M Moskowitz
Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA
J Antimicrob Chemother 56:879-86. 2005..As a prelude to a clinical trial of biofilm susceptibility testing in CF, simulated antibiotic regimens based on either biofilm or conventional susceptibility testing of CF patient isolates were compared...
- Utility of gram staining for evaluation of the quality of cystic fibrosis sputum samplesBindu Nair
Division of Infectious Disease, Department of Pediatrics, University of Washington, Seattle 98015, USA
J Clin Microbiol 40:2791-4. 2002..These data suggest that subjective evaluation combined with comprehensive bacteriology is superior to Gram staining in identifying pathogens in CF sputum...
- Use of real-time PCR with multiple targets to identify Pseudomonas aeruginosa and other nonfermenting gram-negative bacilli from patients with cystic fibrosisXuan Qin
Department of Laboratory Medicine, Therapeutics Development Network Resource Center for Microbiology, Children s Hospital and Regional Medical Center, University of Washington, Seattle, Washington, USA
J Clin Microbiol 41:4312-7. 2003..Given the diversity of these CF isolates, real-time PCR with a combination of two target sequences appears to be the optimum choice for identification of atypical P. aeruginosa and for non-P. aeruginosa gram-negative isolates...
- Exploratory study of the prevalence and clinical significance of tobramycin-mediated biofilm induction in Pseudomonas aeruginosa isolates from cystic fibrosis patientsDanielle Elliott
Department of Biochemistry, University of Washington, Seattle, WA, USA
Antimicrob Agents Chemother 54:3024-6. 2010..This induction always occurred at the same tobramycin concentration regardless of MIC, suggesting that the mechanisms of killing and induction may be separable...
- Large-insert genome analysis technology detects structural variation in Pseudomonas aeruginosa clinical strains from cystic fibrosis patientsHillary S Hayden
Genome Center, University of Washington, Seattle, WA 98195, USA
Genomics 91:530-7. 2008..aeruginosa and validates a technology that complements emerging, short-read sequencing methods that are better suited to characterizing single-nucleotide polymorphisms than structural variation...
- Conservation of a novel protein associated with an antibiotic efflux operon in Burkholderia cenocepaciaBindu M Nair
Department of Pediatrics, Division of Infectious Diseases, Immunology and Rheumatology, University of Washington, Seattle, WA 98109, USA
FEMS Microbiol Lett 245:337-44. 2005..Identification of strong structural homology to hydrolases and a high degree of conservation in B. cenocepacia suggests an enzymatic function for LlpE, benefiting survival in the cystic fibrosis lung...
- Pilus-mediated epithelial cell death in response to infection with Burkholderia cenocepaciaK John Cheung
Division of Infectious Diseases, Immunology and Rheumatology, Children s Hospital and Regional Medical Center, 307 Westlake Avenue N, Seattle, WA 98109, USA
Microbes Infect 9:829-37. 2007..Understanding the role of cbl pili in the pathogenesis of B. cenocepacia infections offers the potential for decreasing the virulence of these potentially life-threatening organisms in CF patients...
- Optimized In Vitro Antibiotic Susceptibility Testing Method for Small-Colony Variant Staphylococcus aureusMimi R Precit
University of Washington, Seattle, Washington, USA
Antimicrob Agents Chemother 60:1725-35. 2016..With clinical correlation, this AST method and these results may prove useful in directing treatment for SCV infections. ..
- The use of polymerase chain reaction for the detection and speciation of bacterial bone and joint infection in childrenKit M Song
Department of Orthopedic Surgery, Children s Hospital and Regional Medical Center of Seattle, Seattle, WA 98105, USA
J Pediatr Orthop 29:182-8. 2009....
- Salicylate induces an antibiotic efflux pump in Burkholderia cepacia complex genomovar III (B. cenocepacia)Bindu M Nair
Division of Infectious Disease, Children s Hospital and Regional Medical Center, Seattle, Washington 98105, USA
J Clin Invest 113:464-73. 2004..cenocepacia and imply that the environment of low iron concentration in the cystic fibrosis lung can induce efflux-mediated resistance, even in the absence of antibiotic selective pressure...
- Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftorSonya L Heltshe
Department of Pediatrics, University of Washington School of Medicine, Seattle Coordinating Center
Clin Infect Dis 60:703-12. 2015..This study examines changes in CF respiratory pathogens with ivacaftor and correlates them with baseline characteristics and clinical response...
- Correlation between an in vitro invasion assay and a murine model of Burkholderia cepacia lung infectionMartin V Cieri
Division of Infectious Disease, Children s Hospital and Regional Medical Center, Seattle, Washington 98105, USA
Infect Immun 70:1081-6. 2002..Correlation between the models for six strains was demonstrated. Our results indicate that a statistical model used to determine invasiveness in an in vitro invasion assay can be used to predict in vivo invasiveness...
- Whole-genome sequence variation among multiple isolates of Pseudomonas aeruginosaDavid H Spencer
The University of Washington Genome Center, Department of Medicine, University of Washington Children s Hospital and Regional Medical Center, Seattle, Washington 98195, USA
J Bacteriol 185:1316-25. 2003..aeruginosa backbone sequence while the strains addressed in this study possess additional genetic material that accounts for at least 10% of their genomes. Approximately half of these additional sequences are novel...
- Evaluation of MicroScan Autoscan for identification of Pseudomonas aeruginosa isolates from cystic fibrosis patientsLisa Saiman
Department of Pediatrics, Division of Infectious Diseases, Columbia University, New York, New York 10032, USA
J Clin Microbiol 41:492-4. 2003..Extending the incubation to 48 h improved identification, but 15% of isolates remained misidentified. The MicroScan Autoscan system cannot be recommended for the identification of P. aeruginosa isolates from CF patients...
- Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesisChristopher H Goss
Department of Medicine, University of Washington Medical Center, Campus Box 356522, 1959 NE Pacific, Seattle, Washington 98195, USA
Thorax 62:360-7. 2007..This review provides a summary of the pathophysiology, clinical epidemiology and microbial epidemiology of a CF pulmonary exacerbation...
- Anti-inflammatory properties of macrolidesThor Wagner
Division of Infectious Diseases Immunology and Rheumatology, Department of Pediatrics, University of Washington School of Medicine, Children s Hospital and Regional Medical Center, Seattle, USA
Pediatr Infect Dis J 26:75-6. 2007
- Comparison of two culture methods for detection of tobramycin-resistant gram-negative organisms in the sputum of patients with cystic fibrosisJill M Van Dalfsen
Chiron Corporation, Seattle, Washington, USA
J Clin Microbiol 40:26-30. 2002..Addition of a tobramycin-containing MacConkey plate to the routine media for sputum culture may provide additional, clinically relevant microbiologic data...
- Ampicillin use in infant fever: a systematic reviewJulie C Brown
Division of General Academic Pediatrics, Department of Pediatrics, University of Washington, Seattle, WA 98105 0371, USA
Arch Pediatr Adolesc Med 156:27-32. 2002..To estimate the prevalence of perinatal Listeria monocytogenes and enterococcal infections in outpatient febrile infants and to evaluate the need to treat with ampicillin...
- Factors affecting the incidence of Stenotrophomonas maltophilia isolation in cystic fibrosisGavin R Graff
Department of Child Health, University of Missouri Columbia, Columbia, MO 65212, USA
Chest 121:1754-60. 2002....
- Anaerobic killing of mucoid Pseudomonas aeruginosa by acidified nitrite derivatives under cystic fibrosis airway conditionsSang Sun Yoon
Department of Molecular Genetics, Biochemistry, and Microbiology, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267 0524, USA
J Clin Invest 116:436-46. 2006..In summary, selective killing by HNO2 may provide novel insights into the important clinical goal of eradicating mucoid P. aeruginosa from the CF airways...
- Analysis of sequential aliquots of hypertonic saline solution-induced sputum from clinically stable patients with cystic fibrosisMoira L Aitken
Department of Medicine, Division of Pulmonary and Critical Care, University of Washington, Seattle 98195, USA
Chest 123:792-9. 2003..The hypothesis was that the duration of SI collection would quantitatively and qualitatively alter the content of the induced sputum...
- Contribution of Burkholderia cenocepacia flagella to infectivity and inflammationTeresa A Urban
Department of Microbiology, University of Virginia Health System, Box 800734, Charlottesville, VA 22908, USA
Infect Immun 72:5126-34. 2004..cenocepacia flagella contribute to virulence in an in vivo infection model, and that induction of host immune responses through interaction with TLR5 may contribute to its overall pathogenic potential...
- Comparison of biophysical and biologic properties of alpha-helical enantiomeric antimicrobial peptidesYuxin Chen
Department of Biochemistry and Molecular Genetics, University of Colorado at Denver, Aurora, CO 80045, USA
Chem Biol Drug Des 67:162-73. 2006..The excellent stability of D-enantiomers to trypsin digestion (no proteolysis by trypsin) compared with the rapid breakdown of the L-enantiomers highlights the advantage of the D-enantiomers and their potential as clinical therapeutics...
- Emergence of new pathogens in CF: the devil we know or the devil we don't know?Jane L Burns
J Pediatr 140:283-4. 2002
- Ribosomal DNA-directed PCR for identification of Achromobacter (Alcaligenes) xylosoxidans recovered from sputum samples from cystic fibrosis patientsLixia Liu
Department of Pediatrics and Communicable Diseases, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
J Clin Microbiol 40:1210-3. 2002..The availability of this assay will enhance identification of A. xylosoxidans, thereby facilitating study of the pathogenic role of this species and improving infection control efforts in CF...
- Effects of azithromycin on P. aeruginosa gene expressionJane Burns; Fiscal Year: 2005..Additionally, specific markers may be identified to predict CF patient response to azithromycin, thus preventing ongoing treatment with ineffective therapy. ..